TB-500: Keep the Molecules Straight
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

TB-500 and thymosin-beta-4 are often discussed as if every study tested the same thing. That shortcut can make the evidence look stronger than it is. Thymosin-beta-4 is involved in actin biology, which helps cells organize and move. Early wound research studied cell migration and wound repair in rats. A result for full-length thymosin-beta-4 cannot automatically validate a fragment or a product sold under another name. Sequence, purity, formulation, and clinical outcomes all need checking. WADA’s 2026 list prohibits thymosin-beta-4 and derivatives such as TB-500 at all times. Neither laboratory activity nor a research-only label establishes a safe recovery treatment.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] Malinda et al. (1999): Thymosin beta4 accelerates wound healing
https://pubmed.ncbi.nlm.nih.gov/10469335/
Primary cell and animal study

[2] WADA 2026 Prohibited List
https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
Official sport rules

[3] FDA 2026 PCAC briefing: TB-500-related bulk drug substances
https://www.fda.gov/media/193349/download
US regulator technical review; not marketing approval

EVIDENCE LIMITATIONS
TB-500 naming in commerce is inconsistent; do not assume a product contains a specific fragment or full-length peptide.
The cited wound paper studied thymosin-beta-4, not every product sold as TB-500.
Do not claim faster human injury recovery or imply a sport ban proves efficacy.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
https://www.facebook.com/reel/2839504279756028/